Merck to Present Advances in HIV Treatment and Prevention Pipeline at EACS 2025

Rowe, New Jersey, USA2025Year10Month9Day——MSD (MSD is the corporate name of Merck & Co., Inc., located in Rahway, New Jersey, U.S.) announced that the company will present the latest research advancements from its HIV treatment and prevention pipeline at the 20th European AIDS Conference (EACS 2025), to be held in Paris, France, from October 15 to 18, 2025. The research updates to be presented by MSD will include:

      "We are pleased to share the latest results from the HIV research field at EACS 2025, including further analysis of the Phase III clinical program for the once-daily, two-drug regimen DOR/ISL, which is currently under review by the U.S. Food and Drug Administration."Vice President of Merck Sharp & Dohme AG LaboratoriesHIVPerson in ChargeLuisa Stamm Ph.D.Said, "By developing daily, weekly, and monthly oral regimens, we hope to provide more diversified treatment and prevention options for people infected with or affected by HIV."

      Partial abstracts to be presented at EACS 2025 include:

      During EACS 2025, MSD will host two thematic symposia open to all registered attendees: Policy Symposium "Curbing the HIV Epidemic in Europe: Policy Challenges and Opportunities," Thursday, October 16, 18:00–19:30 (CEST); Medical Symposium "Optimizing HIV Treatment Management," Friday, October 17, 12:30–14:00 (CEST).

      For more information on the progress of MSD's HIV treatment and prevention clinical research, please click.This link。

About MSD inHIVCommitment in the Field

      MSD has been continuously investing in the HIV field for over 35 years, committed to helping change the landscape of HIV treatment through scientific research advancements and breakthroughs. We lead the development of various drug categories with innovation and support those affected by HIV. Currently, we are developing a series of antiviral drugs aimed at helping people manage and prevent HIV, with the goal of reducing the growing burden of infections worldwide. We hope that people’s lives will no longer be limited by HIV and continue to contribute to the goal of ending the HIV epidemic through transformative innovations, global HIV community collaborations, and efforts to improve accessibility.

About MSD

      At MSD (the corporate name of Merck & Co., Inc. in the United States, based in Rahway, New Jersey), we unite in pursuit of a shared mission: harnessing the power of leading-edge science to save and improve lives around the world. For over 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We are committed to being a top-tier research-intensive biopharmaceutical company—today, we stand at the forefront of innovation, delivering transformative solutions to advance the prevention and treatment of diseases in humans and animals. We have built a diverse and inclusive global workforce that operates responsibly every day, ensuring a safe, sustainable, and healthy future for all people and communities. For more information, visit www.msd.com and follow us on X (formerly Twitter), LinkedIn, and YouTube. 

About MSD China

      China is a crucial part of MSD's global growth strategy. MSD’s China headquarters is located in Shanghai, with a research and development center in Beijing and manufacturing facilities in Hangzhou, Ningbo, and Tianjin, integrating R&D, manufacturing, and commercial operations. We are fully committed to providing the people of China with high-quality innovative medicines, vaccines, and services for the benefit of Chinese society. For more information, please visit the MSD China official website or follow MSD China's official social media account on WeChat. 

MSD Forward-Looking Statements

      MSD is the trade name of Merck & Co., Inc., located in Rahway, New Jersey, USA (hereinafter referred to as "the Company"). This press release contains "forward-looking statements" made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The content herein is based on the current views and expectations of the Company’s management and is subject to significant risks and uncertainties. MSD does not guarantee that its products under development will receive the necessary regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate, or risks or uncertainties arise, actual results may differ materially from those anticipated in the forward-looking statements.

      Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors (including interest rate and currency fluctuations), the impact of pharmaceutical industry regulations and healthcare policies in the United States and other countries, the global trend toward controlling healthcare costs, technological advancements, new products and patents obtained by competitors, inherent challenges in new product development (including obtaining regulatory approval), MSD's ability to accurately predict future market conditions, difficulties or delays in production, instability in international economic and financial conditions and sovereign risks, reliance on the effectiveness of MSD's patent protection and other innovative products, and the risk of patent litigation and/or regulatory actions against the company.

      MSD has no obligation to publicly update any forward-looking statements due to new information, future events, or other reasons. Other factors may cause actual results to materially differ from forward-looking statements; see MSD's 2024 Annual Report on Form 10-K and other documents filed with the U.S. Securities Exchange Commission (available at www.sec.gov).

[1]As of now, doravirine/islatravir has not been approved by the National Medical Products Administration (NMPA) in China.

[2]As of now, lenacapavir has not been approved by the NMPA.

[3]As of now, MK-8527 has not been approved by the NMPA.